Defence Therapeutics Inc. (DTCFF)
| Previous Close | 1.6800 |
| Open | 1.6900 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 1.6900 - 1.6900 |
| 52 Week Range | 1.6500 - 6.4078 |
| Volume | |
| Avg. Volume | 152 |
| Market Cap | 60.78M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1120 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Defence Reports Effective Control of Cervical Cancer Growth in Response to Its AccuVAC-PT007 Therapeutic Vaccination
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report potent pre-clinical results on the use of its AccumTM-linked protein vaccine, AccuVAC-PT007, against cervical cancer. Cervical cancer is a type of cancer affecting the cervix. Various strains
- Newsfile
RETRANSMISSION: Defence's Novel AccuVAC-PTE7 Vaccine Shows Complete Protection from Cervical Cancer
The Company is issuing a clarification news release at the request of IIROC.Vancouver, British Columbia--(Newsfile Corp. - May 18, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focused on the development of novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the development of novel dual-acting AccumTM-linked protein vaccine, AccuVAC-PTE7, dedicated to prote
- Newsfile
Defence Novel AccuVAC-PTE7 Vaccine Shows Complete Protection from Cervical Cancer
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the development of novel dual-acting AccumTM-linked protein vaccine, AccuVAC-PTE7, dedicated to protect from cervical cancer (prophylactic vaccine) or to treat (therapeutic vac
